Clinical spectrum of gross haematuria following SARS-CoV-2 vaccination with mRNA vaccines.

Publication

Clinical spectrum of gross haematuria following SARS-CoV-2 vaccination with mRNA vaccines.

Journal Paper/Review - Dec 21, 2021

Ritter Alexander, Helmchen Birgit, Gaspert Ariana, Bleisch Joerg, Fritschi Barbara C., Buchkremer Florian, Damm Stephanie, Schmid Nicolas, Schachtner Thomas, Seeger Harald

Citation

Ritter A, Helmchen B, Gaspert A, Bleisch J, Fritschi B, Buchkremer F, Damm S, Schmid N, Schachtner T, Seeger H. Clinical spectrum of gross haematuria following SARS-CoV-2 vaccination with mRNA vaccines. Clin Kidney J 2021; 15:961-973.

Type

Journal Paper/Review (English)

Journal

Clin Kidney J 2021; 15

Publication Date

Dec 21, 2021

Issn Print

2048-8505

Pages

961-973

Brief description/objective

Novel messenger RNA (mRNA)-based vaccines play an important role in current vaccination campaigns against SARS-CoV-2. They are highly efficacious and generally well tolerated. Vaccination in patients with immune-mediated kidney diseases is recommended. A number of cases with or relapsing glomerulonephritis shortly after vaccine application have been reported, some of which presented with gross haematuria.